Inhibrx: INBRX-106 + pembro achieves 44% ORR vs 21.4% in HNSCC Phase 2

Inhibrx Biosciences, Inc.

Confirmed ORR 44.0% (11/25) for combo vs 21.4% (6/28) for pembro alone; absolute increase 22.6%.
Three complete responses in combo arm vs zero in control; deeper tumor reductions overall.
Up to 15-fold increase in CD8+ and CD4+ T-cell proliferation in combo arm (vs up to 2.5-fold).
No treatment-related deaths; most common AEs: rash, diarrhea, fatigue, infusion reactions.
Phase 3 HexAgon start Q3 2026; perioperative NSCLC study later this quarter; metastatic NSCLC in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.